Pembrolizumab Improves Outcomes in Early-Stage and Locally Advanced or Metastatic Triple-Negative Breast Cancer

Updates from the phase III KEYNOTE-522 and KEYNOTE-355 trials demonstrate the benefits of pembrolizumab added to chemotherapy in early-stage and locally advanced or metastatic triple-negative breast cancer, respectively.

Detalles Bibliográficos
Autor principal: Jacobson, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Conference Perspectives: Highlights from SABCS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963307/
https://www.ncbi.nlm.nih.gov/pubmed/35348777
http://dx.doi.org/10.1093/oncolo/oyac014
Descripción
Sumario:Updates from the phase III KEYNOTE-522 and KEYNOTE-355 trials demonstrate the benefits of pembrolizumab added to chemotherapy in early-stage and locally advanced or metastatic triple-negative breast cancer, respectively.

Ejemplares similares